Japanese pharmaceutical executive compensation is significantly below that of US and European peers, while insufficient equity incentives may affect shareholder returns
AI summary card
Japanese pharmaceutical executive compensation is significantly below that of US and European peers, while insufficient equity incentives may affect shareholder returns
Bernstein points out that Japanese CEO compensation is approximately 3-7 times lower than that of US and European peers, with the gap being around 6 times in the pharmaceutical sector. Key reasons include the lifetime employment culture, internal promotion, low external executive mobility, and insufficient equity incentives.
- Japanese CEO compensation is significantly lower than that of US and European peers, with the gap particularly pronounced in the pharmaceutical sector.
- Japanese pharmaceutical CEOs typically assume the top position after approximately 37 years at the same company, significantly longer than the roughly 21-year level among US and European peers.
- Japanese executive compensation remains primarily cash- and bonus-based, lacking stock options, RSUs, and shareholding requirements similar to those in the US market.
- The report believes that management wealth not being tied to the share price weakens alignment with shareholder interests and may encourage scale expansion rather than improving ROE.
- Japan has continued to advance governance reforms since the 2014 Stewardship Code and 2015 Corporate Governance Code, and compensation linked to equity and performance is increasing.
Report interpretation
Overview
The report examines whether Japanese executives are “cheap,” focusing on the structural gap between executive compensation in Japan's pharmaceutical industry and that of US and European peers. It argues that low executive compensation at Japanese companies is not merely a reflection of a frugal culture, but is also related to lifetime employment, seniority-based advancement, internal promotion, low labor-market mobility, cross-shareholdings, and insufficient equity incentives. These mechanisms may result in inadequate alignment between management and shareholders and affect corporate capital efficiency and share-price performance.
Core views
The core view is that Japanese pharmaceutical companies compete globally with US and European companies for innovation, talent, and capital, but their executive compensation systems remain highly domestic in nature. Average compensation for US and European pharmaceutical executives is approximately six times that of Japanese peers. Japanese CEOs typically rise through the ranks within the same company over long periods, reducing pressure for external hiring and high compensation to retain talent. At the same time, the stock-based and performance-linked components of Japanese executive compensation are relatively low, leaving executives' personal wealth insufficiently sensitive to share prices. The report believes that increasing executive share ownership and equity incentives would help improve alignment with shareholder interests. Japan's governance reforms are moving in this direction, but current levels remain well behind those in the US and Europe.
Analysis framework
The report uses a cross-regional comparative framework to compare CEO compensation levels, tenure, promotion paths, and compensation structures at listed pharmaceutical companies in Japan, the US, and Europe. It also analyzes the cultural and institutional reasons for the compensation gap in the context of changes in Japan's corporate governance system. The report further uses accompanying tables to present ratings, prices, target prices, EPS, and P/E valuations for major Japanese pharmaceutical companies.
Methodology notes
Equity incentives
Linking management wealth to share prices and long-term shareholder returns through stock options, RSUs, performance shares, and minimum shareholding requirements.
Comparison of executive compensation in Japan and the US and Europe
The report compares CEO compensation, career paths, and compensation structures across markets, noting that company size and profitability cannot fully explain the 3-7-fold compensation gap.
The Stewardship Code and Corporate Governance Code
Since 2014 and 2015, respectively, Japan has promoted capital efficiency, independent compensation committees, CEO succession planning, and compensation linked to shareholder value.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Japanese pharmaceutical stocksThematic assets of the report
- Strengths
- Progress in governance reforms, a rising proportion of equity incentives, and the need for compensation-system reform driven by globalized operations.
- Weaknesses
- Executive compensation and shareholding levels remain significantly below those in the US and Europe, while internal promotion and lifetime employment culture limit compensation flexibility.
- Comparison
- Compared with US and European pharmaceutical companies, executive compensation at Japanese pharmaceutical companies is approximately six times lower, and the share of stock-based compensation is also lower.
- Risks
- Slow reform progress, insufficient board and shareholder pressure, and cross-shareholding structures that weaken market discipline.
- 4502.JP TakedaCompany covered in the accompanying tables
- Strengths
- As a major Japanese pharmaceutical company, its ratings, target price, and valuation data are presented in the report tables.
- Weaknesses
- Japanese pharmaceutical companies overall continue to face insufficient equity incentives in their compensation structures.
- Comparison
- Compared with European and US pharmaceutical companies, Japanese pharmaceutical companies have weaker executive compensation and shareholding constraints.
- Risks
- Differences in global talent compensation structures may lead to internal compensation inversion and incentive misalignment.
- 4519.JP ChugaiCompany covered in the accompanying tables
- Strengths
- The report tables present its ratings, target price, and EPS/P/E data.
- Weaknesses
- Subject to Japan's domestic compensation system and governance inertia.
- Comparison
- US executive compensation systems rely more heavily on stock-based and long-term incentives.
- Risks
- Insufficient linkage between compensation and shareholder value may affect long-term capital efficiency.
Key data
- Japanese CEO compensation gapApproximately one-third to one-seventh that of US and European peersThe report cites recent surveys indicating that Japanese CEO income is only a fraction of that of US and European peers.
- Japanese pharmaceutical executive compensation gapAverage US and European pharmaceutical executive compensation is approximately 6 times that of Japanese peersBased on data for listed pharmaceutical companies in Japan, Europe, and the US compiled in the report.
- Tenure at the company before Japanese pharmaceutical CEOs assume the top positionApproximately 37 yearsSignificantly higher than the global peer average.
- Tenure at the company before US and European pharmaceutical CEOs assume the top positionApproximately 21 yearsAround 16 years shorter than that of Japanese peers, reflecting greater external mobility and faster promotion.
- Eli Lilly CEO minimum shareholding requirement12 times annual base salaryAn example of executive shareholding requirements at a US pharmaceutical company.
- Japanese pharmaceutical companies covered in the accompanying tables4503.JP、4578.JP、4568.JP、4502.JP、4519.JP、4507.JP、4523.JPIncluding Astellas, Otsuka, Daiichi Sankyo, Takeda, Chugai, Shionogi, and Eisai.
Impact & implications
For investors, compensation-system reform at Japanese pharmaceutical companies may become an important governance variable for improving capital efficiency and shareholder returns. If companies increase stock-based compensation, performance-linked compensation, and management shareholding requirements, executives will face more direct pressure from share prices and capital returns. This could help reduce incentives focused solely on expanding scale and improve ROE and long-term share-price performance.
Risks
- Japanese corporate culture and the lifetime employment system may slow the advancement of executive compensation reforms.
- Cross-shareholdings and relatively weak pressure from external shareholders may reduce management sensitivity to share prices.
- If designed poorly, increased equity incentives could create a short-term share-price focus or compensation disputes.
- Global pharmaceutical companies may face situations in which non-Japanese executives are paid more than the CEO, with shareholding influence mismatched to management scope.
What to watch
- Whether the proportion of stock-based and performance-linked compensation at Japanese pharmaceutical companies continues to rise.
- Whether boards strengthen independent compensation committees, CEO succession plans, and minimum shareholding requirements.
- Whether changes in management shareholding lead to improvements in ROE, capital allocation, and share-price performance.
- The subsequent impact of Japan's corporate governance guidelines, METI incentive-plan guidance, and Tokyo Stock Exchange reforms.
- Changes in ratings, target prices, EPS, and P/E valuations for the major Japanese pharmaceutical companies listed in the accompanying tables.